<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Muhammad Faridz Syahrian</style></author><author><style face="normal" font="default" size="100%">I Nyoman Ehrich Lister</style></author><author><style face="normal" font="default" size="100%">Chrismis Novalinda Ginting</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Evaluating the Therapeutic Potential of Vernonia amygdalina: A Promising Antidiabetic Agent in STZ and Nicotinamide-Induced Rat Model</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Diabetes</style></keyword><keyword><style  face="normal" font="default" size="100%">HbA1c</style></keyword><keyword><style  face="normal" font="default" size="100%">Insulin</style></keyword><keyword><style  face="normal" font="default" size="100%">MDA</style></keyword><keyword><style  face="normal" font="default" size="100%">SOD</style></keyword><keyword><style  face="normal" font="default" size="100%">Vernonia amygdalina</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">February 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">94-99</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; Vernonia amygdalina, commonly known as bitter leaf, has been traditionally used for its potential antidiabetic properties. This study aimed to evaluate the therapeutic potential of Vernonia amygdalina extract (VAE) in ameliorating hyperglycemia using a streptozotocin (STZ) and high-fat diet (HFD)-induced rat model of diabetes. &lt;strong&gt;Methods:&lt;/strong&gt; Sixty male Wistar rats were divided into six groups: normal control, diabetic control, and four treatment groups receiving different doses of VAE (100, 300, and 500 mg/kg body weight) orally for eight weeks. Diabetes was induced in rats by a single intraperitoneal injection of STZ (55 mg/kg) after four weeks of Nicotinamid feeding. Body weight, fasting blood glucose levels, HbA1c, serum insulin levels, superoxide dismutase (SOD) activity, and malondialdehyde (MDA) levels were measured. &lt;strong&gt;Results: &lt;/strong&gt;Treatment with VAE significantly reduced fasting blood glucose levels in a dose-dependent manner compared to the diabetic control group (p &amp;lt; 0.05). VAE administration also led to a significant decrease in HbA1c levels and an increase in serum insulin levels in a dosedependent manner (p &amp;lt; 0.05). Furthermore, VAE supplementation restored SOD activity and reduced MDA levels, indicating improved antioxidant status in the treated groups (p &amp;lt; 0.05). &lt;strong&gt;Conclusion: &lt;/strong&gt;This study demonstrates the therapeutic potential of Vernonia amygdalina as an antidiabetic agent in the STZ and HFD-induced rat model of diabetes. VAE supplementation effectively reduced fasting blood glucose levels, improved glycemic control as indicated by reduced HbA1c levels, and enhanced insulin secretion. Moreover, VAE exhibited antioxidant activity by restoring SOD activity and reducing MDA levels. These findings suggest that Vernonia amygdalina could be a promising natural remedy for the management of diabetes. Further investigations are warranted to elucidate the underlying mechanisms and evaluate its long-term safety and efficacy in humans.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">94</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Muhammad Faridz Syahrian*, I Nyoman Ehrich Lister, Chrismis Novalinda Ginting&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;Faculty of Medicine, Universitas Prima Indonesia, Sumatera Utara, Medan, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Intanri Kurniati</style></author><author><style face="normal" font="default" size="100%">Agustyas Tjiptaningrum</style></author><author><style face="normal" font="default" size="100%">Raja Iqbal Mulya Harahap</style></author><author><style face="normal" font="default" size="100%">Bayu Putra Danan Jaya</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Serum Trace Element Levels in Type 2 DM Patients and its Correlation with Glycemic Control</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Fasting blood glucose</style></keyword><keyword><style  face="normal" font="default" size="100%">glycemic control</style></keyword><keyword><style  face="normal" font="default" size="100%">HbA1c</style></keyword><keyword><style  face="normal" font="default" size="100%">trace element serum</style></keyword><keyword><style  face="normal" font="default" size="100%">Type 2 diabetes mellitus</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">660-663</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; Type 2 diabetes mellitus, a chronic metabolic disorder, is known to impact serum trace element levels. Objectives: to investigates the association between serum trace elements (Co, Cr, and Cu) and glycemic control in individuals with type 2 diabetes. &lt;strong&gt;Material and Methods:&lt;/strong&gt; A 209 type 2 diabetes patients from Dr. H. Abdul Moeloek Hospital in Bandar Lampung and Hasan Sadikin Hospital in Bandung participated in the study. Patients underwent assessments for serum trace element levels (Co, Cr, and Cu) and glycemic control indicators (FBG and HbA1c). &lt;strong&gt;Results:&lt;/strong&gt; Results indicated significantly lower Co levels in uncontrolled diabetes versus controlled cases (P&amp;lt;0.05). Co, Cr, and Cu levels displayed a significant negative correlation with HbA1c (P&amp;lt;0.05), while Cr and Cu showed a significant negative correlation with FBG (P&amp;lt;0.05). Age did not show significant correlations with serum trace element levels. &lt;strong&gt;Conclusion:&lt;/strong&gt; serum trace element levels (Co, Cr, Cu) are inversely linked to glycemic control in type 2 diabetes individuals.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">660</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Intanri Kurniati&lt;sup&gt;1&lt;/sup&gt;*, Agustyas Tjiptaningrum&lt;sup&gt;1&lt;/sup&gt;, Raja Iqbal Mulya Harahap&lt;sup&gt;2&lt;/sup&gt;, Bayu Putra Danan Jaya&lt;sup&gt;3&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Clinical Pathology, Faculty of Medicine, Universitas Lampung, Bandar Lampung, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Clinical Pathology, Faculty of Medicine, Universitas Padjajaran – Hasan Sadikin Hospital, Bandung, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;3&lt;/sup&gt;Histology and Pathology Laboratory, Faculty of Medicine, Universitas Lampung, Bandar Lampung, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">M Vani</style></author><author><style face="normal" font="default" size="100%">P Uma Maheswari Devi</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Seagrass in the Control of Hyperglycemic and Hyperlipidemic States of Streptozotocin Induced Diabetic Rats</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Diabetes mellitus</style></keyword><keyword><style  face="normal" font="default" size="100%">FBG</style></keyword><keyword><style  face="normal" font="default" size="100%">Halophila beccarii</style></keyword><keyword><style  face="normal" font="default" size="100%">HbA1c</style></keyword><keyword><style  face="normal" font="default" size="100%">HDL</style></keyword><keyword><style  face="normal" font="default" size="100%">LDL</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">November 2020</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><pages><style face="normal" font="default" size="100%">1716-1721</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;The present study intended to evaluate the beneficial effects of the seagrass &lt;em&gt;Halophila beccarii,&lt;/em&gt; against induced diabetes mellitus in rat models. &lt;em&gt;Halophila beccarii &lt;/em&gt;is a type of Seagrass abundant in Pulicat Lake of Andhra Pradesh, India. &lt;strong&gt;Objective:&lt;/strong&gt; Evaluating the anti-hyperglycemic and anti-hyperlipidemic properties of seagrass extract in comparison with standards. &lt;strong&gt;Materials and Methods: &lt;/strong&gt;STZ induced diabetic rat models were adopted to analyze the effect of long-term treatment with seagrass extract on blood glucose, HbA1c and serum lipids. &lt;strong&gt;Results:&lt;/strong&gt; The methanolic extract of seagrass demonstrated a significant drop of blood glucose levels (52%), in diabetic rats, after 6 h of supplementation. After 40 days of treatment with 500 mg/day of seagrass extract, STZ diabetic rats exhibited tremendous decrease in fasting blood glucose with significant improvement in glycemic control as evidenced by controlled levels of HbA1c. Lower levels of triglycerides, total cholesterol, LDL and VLDL cholesterols and higher levels of HDL cholesterol in STZ-induced diabetic rats provided an evidence for significant anti hyperlipidemic property of seagrass extract. &lt;strong&gt;Conclusion: &lt;/strong&gt;Phytochemicals of seagrass like phenols, flavonoids and bioactive lipids contribute to the anti-hyperglycemic and anti-hyperlipidemic activities and &lt;em&gt;Halophila beccarii &lt;/em&gt;extract serves as a natural supplement in the management of diabetes.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6s</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">1716</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;M Vani, P Uma Maheswari Devi* &lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;Department of Applied Microbiology &amp;amp; Biochemistry, Sri Padmavati Mahila Visvavidyalayam, Tirupati, INDIA.&lt;/p&gt;
</style></auth-address></record></records></xml>